Literature DB >> 19837659

Alphav beta3 integrin limits the contribution of neuropilin-1 to vascular endothelial growth factor-induced angiogenesis.

Stephen D Robinson1, Louise E Reynolds, Vassiliki Kostourou, Andrew R Reynolds, Rita Graça da Silva, Bernardo Tavora, Marianne Baker, John F Marshall, Kairbaan M Hodivala-Dilke.   

Abstract

Both vascular endothelial growth factor receptors (VEGFR) and integrins are major regulators of VEGF-induced angiogenesis. Previous work has shown that beta3 integrin can regulate negatively VEGFR2 expression. Here we show that beta3 integrin can regulate negatively VEGF-mediated angiogenesis by limiting the interaction of the co-receptor NRP1 (neuropilin-1) with VEGFR2. In the presence of alphav beta3 integrin, NRP1 contributed minimally to VEGF-induced angiogenic processes in vivo, ex vivo, and in vitro. Conversely, when beta3 integrin expression is absent or low or its function is blocked with RGD-mimetic inhibitors, VEGF-mediated responses became NRP1-dependent. Indeed, combined inhibition of beta3 integrin and NRP1 decreased VEGF-mediated angiogenic responses further than individual inhibition of these receptors. We also show that alphav beta3 integrin can associate with NRP1 in a VEGF-dependent fashion. Our data suggest that beta3 integrin may, in part, negatively regulate VEGF signaling by sequestering NRP1 and preventing it from interacting with VEGFR2.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19837659      PMCID: PMC2797167          DOI: 10.1074/jbc.M109.030700

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  59 in total

1.  Primary mouse endothelial cell culture for assays of angiogenesis.

Authors:  Louise E Reynolds; Kairbaan M Hodivala-Dilke
Journal:  Methods Mol Med       Date:  2006

2.  Interactions of VEGF isoforms with VEGFR-1, VEGFR-2, and neuropilin in vivo: a computational model of human skeletal muscle.

Authors:  Feilim Mac Gabhann; Aleksander S Popel
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-09-15       Impact factor: 4.733

Review 3.  Vascular endothelial growth factor receptors: expression and function in solid tumors.

Authors:  Jane S Wey; Oliver Stoeltzing; Lee M Ellis
Journal:  Clin Adv Hematol Oncol       Date:  2004-01

Review 4.  The neuropilins and their role in tumorigenesis and tumor progression.

Authors:  Noga Guttmann-Raviv; Ofra Kessler; Niva Shraga-Heled; Tali Lange; Yael Herzog; Gera Neufeld
Journal:  Cancer Lett       Date:  2006-01-08       Impact factor: 8.679

5.  Evidence from site-directed mutagenesis that the cytoplasmic domain of the beta3 subunit influences the conformational state of the alphaVbeta3 integrin ectodomain.

Authors:  E Schaffner-Reckinger; N H Brons; N Kieffer
Journal:  Thromb Haemost       Date:  2001-04       Impact factor: 5.249

6.  Antiangiogenic activity of semisynthetic biotechnological heparins: low-molecular-weight-sulfated Escherichia coli K5 polysaccharide derivatives as fibroblast growth factor antagonists.

Authors:  Marco Presta; Pasqua Oreste; Giorgio Zoppetti; Mirella Belleri; Elena Tanghetti; Daria Leali; Chiara Urbinati; Antonella Bugatti; Roberto Ronca; Stefania Nicoli; Emanuela Moroni; Helena Stabile; Maura Camozzi; German Andrés Hernandez; Stefania Mitola; Patrizia Dell'Era; Marco Rusnati; Domenico Ribatti
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-10-28       Impact factor: 8.311

7.  Vascular endothelial growth factor is an autocrine survival factor for breast tumour cells under hypoxia.

Authors:  Martin P Barr; David J Bouchier-Hayes; Judith J Harmey
Journal:  Int J Oncol       Date:  2008-01       Impact factor: 5.650

Review 8.  Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.

Authors:  Anand Veeravagu; Andrew R Hsu; Weibo Cai; Lewis C Hou; Victor C K Tse; Xiaoyuan Chen
Journal:  Recent Pat Anticancer Drug Discov       Date:  2007-01       Impact factor: 4.169

9.  Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels.

Authors:  P C Brooks; A M Montgomery; M Rosenfeld; R A Reisfeld; T Hu; G Klier; D A Cheresh
Journal:  Cell       Date:  1994-12-30       Impact factor: 41.582

10.  Neuropilin-1 is required for endothelial tip cell guidance in the developing central nervous system.

Authors:  Holger Gerhardt; Christiana Ruhrberg; Alexandra Abramsson; Hajime Fujisawa; David Shima; Christer Betsholtz
Journal:  Dev Dyn       Date:  2004-11       Impact factor: 3.780

View more
  45 in total

1.  Neuropilin-1 stimulates tumor growth by increasing fibronectin fibril assembly in the tumor microenvironment.

Authors:  Usman Yaqoob; Sheng Cao; Uday Shergill; Kumaravelu Jagavelu; Zhimin Geng; Meng Yin; Thiago M de Assuncao; Ying Cao; Anna Szabolcs; Snorri Thorgeirsson; Martin Schwartz; Ju Dong Yang; Richard Ehman; Lewis Roberts; Debabrata Mukhopadhyay; Vijay H Shah
Journal:  Cancer Res       Date:  2012-06-27       Impact factor: 12.701

Review 2.  Signal transduction by vascular endothelial growth factor receptors.

Authors:  Sina Koch; Lena Claesson-Welsh
Journal:  Cold Spring Harb Perspect Med       Date:  2012-07       Impact factor: 6.915

Review 3.  In vitro models for the evaluation of angiogenic potential in bone engineering.

Authors:  Elisabetta Cenni; Francesca Perut; Nicola Baldini
Journal:  Acta Pharmacol Sin       Date:  2010-11-01       Impact factor: 6.150

4.  Neuropilin-2 regulates α6β1 integrin in the formation of focal adhesions and signaling.

Authors:  Hira Lal Goel; Bryan Pursell; Clive Standley; Kevin Fogarty; Arthur M Mercurio
Journal:  J Cell Sci       Date:  2012-02-02       Impact factor: 5.285

Review 5.  Neuropilin Functions as an Essential Cell Surface Receptor.

Authors:  Hou-Fu Guo; Craig W Vander Kooi
Journal:  J Biol Chem       Date:  2015-10-08       Impact factor: 5.157

6.  A ligand-independent VEGFR2 signaling pathway limits angiogenic responses in diabetes.

Authors:  Carmen M Warren; Safiyyah Ziyad; Anaïs Briot; Aaron Der; M Luisa Iruela-Arispe
Journal:  Sci Signal       Date:  2014-01-07       Impact factor: 8.192

7.  Pharmacological Inhibition of β3 Integrin Reduces the Inflammatory Toxicities Caused by Oncolytic Adenovirus without Compromising Anticancer Activity.

Authors:  Ashley Browne; Laura A Tookman; Carin K Ingemarsdotter; Russell D Bouwman; Katrina Pirlo; Yaohe Wang; Iain A McNeish; Michelle Lockley
Journal:  Cancer Res       Date:  2015-05-14       Impact factor: 12.701

Review 8.  Semaphorin3a signaling, podocyte shape, and glomerular disease.

Authors:  Alda Tufro
Journal:  Pediatr Nephrol       Date:  2014-01-26       Impact factor: 3.714

9.  Endothelial-Rac1 is not required for tumor angiogenesis unless alphavbeta3-integrin is absent.

Authors:  Gabriela D'Amico; Stephen D Robinson; Mitchel Germain; Louise E Reynolds; Gareth J Thomas; George Elia; Garry Saunders; Marcus Fruttiger; Victor Tybulewicz; Georgia Mavria; Kairbaan M Hodivala-Dilke
Journal:  PLoS One       Date:  2010-03-22       Impact factor: 3.240

Review 10.  Enhancing integrin function by VEGF/neuropilin signaling: implications for tumor biology.

Authors:  Hira Lal Goel; Arthur M Mercurio
Journal:  Cell Adh Migr       Date:  2012-10-17       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.